Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hepatic first-pass metabolism in liver disease.

Literature DB >> 391462

Hepatic first-pass metabolism in liver disease.

T F Blaschke, P C Rubin.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 1979 PMID： 391462 DOI： 10.2165/00003088-197904060-00002

Source DB: PubMed Journal: Clin Pharmacokinet ISSN： 0312-5963 Impact factor: 6.447

× No keyword cloud information.

29 in total

1. Effect of portacaval shunt on the disposition of drugs with and without first-pass effect.

Authors: R Gugler; P Lain; D L Azarnoff
Journal: J Pharmacol Exp Ther Date: 1975-12 Impact factor: 4.030

2. Importance of "first-pass elimination" for interindividual differences in steady-state concentrations of the adrenergic beta-receptor antagonist alprenolol.

Authors: G Alván; M Lind; B Mellström; C von Bahr
Journal: J Pharmacokinet Biopharm Date: 1977-06

3. Clinical pharmacokinetics of hydrallazine.

Authors: T Talseth
Journal: Clin Pharmacokinet Date: 1977 Sep-Oct Impact factor: 6.447

4. Effect of phenobarbitone on the disposition of lignocaine and warfarin in the dog.

Authors: M Esquivel; T F Blaschke; G H Snidow; P J Meffin
Journal: J Pharm Pharmacol Date: 1978-12 Impact factor: 3.765

Review 5. Pulmonary disease and drug kinetics.

Authors: P du Souich; A J McLean; D Lalka; S Erill; M Gibaldi
Journal: Clin Pharmacokinet Date: 1978 Jul-Aug Impact factor: 6.447

Review 6. The hepatic artery: subservient to hepatic metabolism or guardian of normal hepatic clearance rates of humoral substances.

Authors: W W Lautt
Journal: Gen Pharmacol Date: 1977

7. Elimination of paracetamol in chronic liver disease.

Authors: R Arnman; R Olsson
Journal: Acta Hepatogastroenterol (Stuttg) Date: 1978-08

8. The influence of cirrhosis on steady-state blood concentrations of unbound propranolol after oral administration.

Authors: A J Wood; D M Kornhauser; G R Wilkinson; D G Shand; R A Branch
Journal: Clin Pharmacokinet Date: 1978 Nov-Dec Impact factor: 6.447

9. Influence of congestive heart failure on prazosin kinetics.

Authors: P Jaillon; P Rubin; Y G Yee; R Ball; R Kates; D Harrison; T Blaschke
Journal: Clin Pharmacol Ther Date: 1979-06 Impact factor: 6.875

10. Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration.

Authors: N Chirstophidis; F J Vajda; I Lucas; O Drummer; W J Moon; W J Louis
Journal: Clin Pharmacokinet Date: 1978 Jul-Aug Impact factor: 6.447

25 in total

Review 1. Clinical pharmacokinetics in patients with liver disease.

Authors: A J McLean; D J Morgan
Journal: Clin Pharmacokinet Date: 1991-07 Impact factor: 6.447

Review 2. Drug kinetics and hepatic blood flow.

Authors: C F George
Journal: Clin Pharmacokinet Date: 1979 Nov-Dec Impact factor: 6.447

Review 3. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.

Authors: Jochen Graff; Sebastian Harder
Journal: Clin Pharmacokinet Date: 2013-04 Impact factor: 6.447

9. Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease.

Authors: S Krähenbühl; P Grass; A Surve; K Kutz; J Reichen
Journal: Eur J Clin Pharmacol Date: 1993 Impact factor: 2.953

Review 10. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

Authors: Roger K Verbeeck
Journal: Eur J Clin Pharmacol Date: 2008-09-02 Impact factor: 2.953